Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension... Show more
Tenax Therapeutics is a Phase 3 development-stage biotechnology company focused on cardiovascular and pulmonary diseases with high unmet medical need, anchored by its lead program, TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and K-ATP (ATP-sensitive potassium) channel activator originally developed for intravenous use in acutely decompensated heart failure; Tenax's thesis is that chronic oral dosing could translate its hemodynamic benefits into a maintenance setting for PH-HFpEF, a condition with no approved therapy in the U.S.
Structurally, the company's positioning is now defined by concentration rather than diversification. Its previously deprioritized imatinib program (TNX-201) is no longer a meaningful near-term driver, leaving levosimendan as effectively the entire investment case. The advantage lies in a first-mover opportunity within an underserved patient population; the risk is that the value of the franchise hinges on whether regulators accept a subgroup-based approval argument drawn from the LEVEL study's prespecified analyses in more severely impaired patients.
The single most consequential upcoming catalyst is the regulatory engagement itself. Tenax has indicated it intends to request a Type C meeting with the FDA to present the full LEVEL dataset and to seek EMA scientific consultation, with discussions centered on an enriched-population approach focused on patients with lower baseline six-minute walk distances. In that prespecified subgroup, the company reported a 26.3-meter improvement versus placebo, along with favorable changes in NT-proBNP (a biomarker of heart-failure stress) and right ventricular systolic pressure, albeit on a nominal statistical basis.
Whether regulators endorse a path forward—and whether any redesigned or confirmatory trial is feasible within the company's cash runway—will likely determine the trajectory of the stock. Beyond clinical and regulatory milestones, capital allocation is a secondary catalyst: as a pre-revenue company, Tenax may need to raise additional capital, and the terms and timing of any financing will shape investor perception of dilution risk.
Analyst sentiment has become more cautious and more dispersed. Following the August 2026 readout, firms including Guggenheim, William Blair, Chardan Capital, and Evercore ISI downgraded or moved to hold-equivalent ratings, while several price targets were cut sharply. Nevertheless, consensus data aggregators still show an overall "Buy" profile, with roughly six buy ratings and four hold ratings among recent coverage. The average 12-month price target sits near the high-single to low-double digits, but the range is extraordinarily wide—from as low as $4 to as high as $35—underscoring how binary the regulatory outcome is perceived to be.
Tenax's outlook is less tied to traditional macro variables and more to the financing environment for clinical-stage biotechnology. Rising or falling interest rates matter indirectly through the cost of capital and investors' appetite for pre-revenue, high-risk assets; in periods of tighter liquidity, development-stage companies with binary catalysts often trade at a discount. Inflation trends and healthcare-policy shifts have limited direct bearing on a company with no commercial product, but broader regulatory climate—particularly FDA receptiveness to subgroup analyses and expedited pathways—is a decisive industry-level force.
On the demand side, the aging of the global population and the rising prevalence of heart failure with preserved ejection fraction support the long-term addressable market for PH-HFpEF therapies. This demographic tailwind persists regardless of short-term trial outcomes, but its monetization depends entirely on clinical and regulatory success.
Tickeron's Trend Prediction Engine is an AI-powered forecasting tool designed to help traders assess whether a stock, ETF (exchange-traded fund), or other asset may trend bullish, bearish, or sideways over the coming week or month. It is built to help users spot developing trends, evaluate possible breakouts or reversals, and explore predictions across a broad universe of tradable instruments. The product includes searchable prediction categories, historical context, and alert-oriented functionality to support timely decision-making. For investors tracking binary-outcome names such as Tenax Therapeutics, tools like this can complement fundamental research with a systematic view of emerging price trends. Explore the platform to see how these signals apply to your watchlist.
Looking into 2026 and beyond, Tenax's future hinges on a small number of high-impact variables. The first is regulatory strategy: a favorable FDA or EMA response to the enriched-population proposal could materially change the risk-reward profile by defining a viable approval route, while a negative signal would likely compress the opportunity set. The second is trial design and execution—any confirmatory study will need to balance statistical rigor against cost and timeline, a delicate trade-off for a company with finite cash.
Cost-structure evolution is another theme. With roughly $113 million in cash on the balance sheet, runway management and financing strategy will be closely scrutinized, particularly against the backdrop of securities class-action litigation announced in late 2026. Long-term, margin sustainability and commercialization economics are theoretical until an approval materializes, so investors are effectively underwriting clinical and regulatory execution rather than near-term profitability.
Consensus expectations reflect this binary setup. Analyst ratings remain nominally positive on average, but the wide dispersion in price targets—and the rapid succession of downgrades after the LEVEL readout—signals that professional sentiment is split between those who see meaningful optionality in the subgroup strategy and those awaiting clearer regulatory clarity. As always, any price targets cited here represent external analyst expectations, not this publication's own forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PLTD | 6.04 | 0.38 | +6.71% |
| Direxion Dailly PLTR Bear 1X ETF (PLTD) | |||
| XKRE | 25.68 | N/A | N/A |
| Corgi U.S. Regional Banks 2x Daily ETF (XKRE) | |||
| FLRG | 38.19 | -1.16 | -2.95% |
| Fidelity U.S. Multifactor ETF (FLRG) | |||
| NFEB | 28.63 | -1.04 | -3.49% |
| Innovator Growth-100 Power Buffer ETF - February (NFEB) | |||
| FTC | 151.82 | -7.48 | -4.70% |
| First Trust Large Cap Growth AlphaDEX Fund (FTC) | |||
A.I.dvisor indicates that over the last year, TENX has been closely correlated with SION. These tickers have moved in lockstep 93% of the time. This A.I.-generated data suggests there is a high statistical probability that if TENX jumps, then SION could also see price increases.
| Ticker / NAME | Correlation To TENX | 1D Price Change % | ||
|---|---|---|---|---|
| TENX | 100% | -10.07% | ||
| SION - TENX | 93% Closely correlated | -4.88% | ||
| AVXL - TENX | 47% Loosely correlated | -11.39% | ||
| CORT - TENX | 41% Loosely correlated | -2.09% | ||
| HRTX - TENX | 40% Loosely correlated | -4.39% | ||
| MGNX - TENX | 32% Poorly correlated | -1.01% | ||
More | ||||
a developer of novel therapeutic products
Industry Biotechnology
It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +9.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where TENX advanced for three days, in 191 of 234 cases, the price rose further within the following month. The odds of a continued upward trend are 82%.
TENX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TENX as a result. In 73 of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 79%.
The Moving Average Convergence Divergence Histogram (MACD) for TENX turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 27 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
TENX moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TENX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for TENX entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 6 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.557) is normal, around the industry mean (3.596). P/E Ratio (-1.142) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (443.347).
The Tickeron Price Growth Rating for this company is 87 (best 1 - 100 worst), indicating slightly worse than average price growth. TENX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TENX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.